We have set a high standard

Last week the CieBOM in the Netherlands proposed new criteria for clinical relevance in oncology therapies studied in non-randomized clinical trials. An increasing number of treatments achieve EMA registration based on non-randomized trials, especially in rare indications. CieBOM currently does not evaluate these therapies as it only decides on therapies that were studied in an

Lees meer